Skip to main content

Table 1 Clinical characteristics of the enrolled patients in the training group and the external validation group

From: Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study

  Training group (n = 60) Validation group (n = 32) p value
Gender
Male 49 24 0.993
Female 11 8  
Age (years) 60.60 ± 9.33 62.50 ± 5.86 0.340
Serum CA125 (Elevated) 6 1 0.300
Serum CA199 (Elevated) 8 5 0.241
Serum CEA (Elevated) 18 9 0.112
Serum albumin (Reduced) 29 1 0.315
Borrmann typing
I–II 32 10 0.010*
III–IV 28 22  
Tumor thickness (cm)    
  18.19 ± 5.75 15.39 ± 5.14 0.036*
Degree of differentiation
Low 25 20 0.087
Middle-high 35 12  
T-staging before NAC
4 31 21 0.122
2–3 29 11  
N-staging before NAC
0–1 38 17 0.578
2–3 22 15  
TRG
0 19 4 0.218
1 12 10  
2 15 9  
3 14 9  
  1. NAC neoadjuvant chemotherapy, TRG tumor regression grade, CA carbohydrate antigen, CA199 (normal range 0.01–37 U/mL), CA125 (normal range 0.01–35 U/mL), CEA carcinoembryonic antigen (normal range 0–5 ng/mL)
  2. *Statistically significant level: p < 0.05